Spanish biosimilars company buys Genhelix to expand production capacity

Genhelix facility in Leon, Spain--Courtesy of Genhelix

Biosimilars are expected to be a big revenue generator for the companies with the expertise and the facilities capable of producing them. mAbxience, a Swiss-based subsidiary of a Spanish company, says it intends to be among those and has bought a competitor in Spain to move those ambitions down the road.

mAbxience, a unit of Spain's Chemo Group, announced today that is has acquired Genhelix, a contract manufacturer development organization, in Leon, Spain, that is dedicated to making monoclonal antibodies (mAbs) and other recombinant proteins used in biologics. Terms of the deal were not disclosed.

Genhelix's facility, which has been approved by European regulators, currently has a capacity for clinical stage operations, but mAbxience has bigger ideas in mind. It said it intends to expand the facility to 16,000 liters. The company, which has four biosimilars under development, says it already owns PharmADN, a biotech facility in Buenos Aires, Argentina.

The acquisition, mAbxience said, will help it with its plan to develop and manufacture biosimilars for the European and Asian markets. "The acquisition of Genhelix is very important news in terms of consolidating mAbxience as a biosimilar medicines leader in Europe, and it will allow us to move forward in our strategy for manufacturing products that meet the highest quality standards and for obtaining significant cost savings," Carlos Bañado, mAbxience managing director, said in a statement.

Biosimilars are already being sold in Europe and are expected to eventually be a big deal in the U.S. as well and a lot of players are positioning themselves to tap the market. India's Glenmark, which is working on both novel monoclonal antibodies and biosimilars, said a week ago it had brought online a new mAb manufacturing facility in Switzerland for its clinical work. French contract manufacturer Novasep said last month it had completed an expansion of its highly potent active pharmaceutical ingredients (HPAPI) manufacturing operations at its plant in Le Mans, France.

- here's the announcement